Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €21.54 EUR
Change Today +0.31 / 1.46%
Volume 11.9K
M3V On Other Exchanges
Symbol
Exchange
Xetra
As of 3:35 PM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

mevis medical solutions ag (M3V) Snapshot

Open
€21.01
Previous Close
€21.23
Day High
€22.00
Day Low
€21.01
52 Week High
04/29/15 - €22.49
52 Week Low
10/16/14 - €12.38
Market Cap
39.2M
Average Volume 10 Days
7.3K
EPS TTM
€2.16
Shares Outstanding
1.8M
EX-Date
06/10/15
P/E TM
10.0x
Dividend
€0.04
Dividend Yield
--
Current Stock Chart for MEVIS MEDICAL SOLUTIONS AG (M3V)

Related News

No related news articles were found.

mevis medical solutions ag (M3V) Related Businessweek News

No Related Businessweek News Found

mevis medical solutions ag (M3V) Details

MeVis Medical Solutions AG, together with its subsidiaries, develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms. Its clinical focuses include image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. This segment also offers image and risk analysis for planning liver surgery and tumor diagnostics in connection with clinical studies of pharmaceutical companies. The company has operations in the United States and Europe. MeVis Medical Solutions AG was founded in 1992 and is based in Bremen, Germany.

Founded in 1992

mevis medical solutions ag (M3V) Top Compensated Officers

Chairman of the Executive Board and Chief Exe...
Total Annual Compensation: €306.3K
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €243.4K
Compensation as of Fiscal Year 2013.

mevis medical solutions ag (M3V) Key Developments

MeVis Medical Solutions AG Proposes Dividend

In light of the new shareholder structure, the supervisory board and management board of MeVis Medical Solutions AG proposed a dividend in the amount of the statutory minimum dividend of EUR 0.04 per share to the Annual General Meeting.

MeVis Medical Solutions AG Announces Earnings Results for the Fiscal Year 2014

MeVis Medical Solutions AG announced earnings results for the fiscal year 2014. The revenues generated in 2014 amounted to EUR 13.1 million, with 2% slightly above the previous year's revenues of EUR 12.8 million. At that, the revenues from services rose significantly from EUR 0.3 million to EUR 0.7 million, licensing business could be increased slightly from EUR 6.5 million to EUR 6.6 million, and maintenance revenues decreased marginally from EUR 5.9 million to EUR 5.7 million. The increase in sales is entirely attributable to the Digital Mammography segment, where sales rose from EUR 9.4 million to EUR 9.8 million, while sales in the other Diagnostics segment fell slightly from EUR 3.4 million to EUR 3.3 million. For the past fiscal year this leads to a EUR 0.5 million decline in EBIT (earnings before interest and taxes) to EUR 3.9 million, which corresponds to a still attractive EBIT margin of 30 % (previous year 34 %). Following a significantly improved financial result of EUR 1.1 million compared to loss of EUR 0.4 million and a strong increase in tax expense of EUR 1.2 million compared to EUR 0.3 million a year ago, a profit after taxes of EUR 3.7 million could be generated, corresponding to earnings per share of EUR 2.16 compared to EUR 2.14 a year ago.

MeVis Medical Solutions AG Revises Guidance for the Fiscal Year 2015

MeVis Medical Solutions AG raised its forecast for the fiscal year 2015 due to the sale of treasury shares. For the year 2015 revenues are expected to remain stable at between EUR 13.0 million and EUR 13.5 million (as in the previous forecast). For the EBIT (earnings before interest and taxes), a decrease over the previous year to EUR 2.0 million to EUR 2.5 million continues to be expected (as in the previous forecast).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
M3V:GR €21.54 EUR +0.31

M3V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for M3V.
View Industry Companies
 

Industry Analysis

M3V

Industry Average

Valuation M3V Industry Range
Price/Earnings 8.0x
Price/Sales 2.1x
Price/Book 1.1x
Price/Cash Flow 5.6x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEVIS MEDICAL SOLUTIONS AG, please visit www.mevis.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.